Trial Profile

Effisayil ON: An open-label, long term extension study to assess the safety and efficacy of spesolimab treatment in patients with Generalized Pustular Psoriasis (GPP)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Spesolimab (Primary) ; Spesolimab (Primary)
Indications Generalised pustular psoriasis
Focus Adverse reactions
Acronyms Effisayil ON
Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharma KG; LEO Pharma AB

Most Recent Events

27 Mar 2026 Results presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting.1,2, according to LEO Pharma A/S Media Release.
27 Mar 2026 Results presented in the LEO Pharma A/S Media Release.
24 Dec 2024 Planned End Date changed from 20 Jan 2028 to 27 Apr 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com